All In Biotech

Drug Trial Radar · NCT04265651

Study of Infigratinib in Children With Achondroplasia

Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL 2

Last checked: Nov 20, 2026Latest source record: Oct 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

84

Actual

Start

Mar 10, 2020

Primary completion

Oct 21, 2024

Study completion Oct 21, 2024

Sponsor

Sponsor type
Industry
First posted
Feb 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR) 1-3-selective tyrosine kinase inhibitor, in children 3 to 11 years of age with Achondroplasia (ACH) who previously participated in the PROPEL study (Protocol QBGJ398-001) for at least 6 months. The study includes dose escalation with extended treatment, and dose expansion. The study also includes a PK Substudy to fully characterize the pharmacokinetics of infigratinib in children with ACH.

Conditions

  • Achondroplasia

Interventions

  • Infigratinib 0.016 mg/kgDrug

    Initial cohort dose of infigratinib at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria. Infigratinib tablets to be administered by mouth.

  • Infigratinib 0.032 mg/kgDrug

    Subsequent cohort dose escalation based on protocol-specific criteria. Infigratinib tablets to be administered by mouth.

  • Infigratinib 0.064 mg/kgDrug

    Subsequent cohort dose escalation based on protocol-specific criteria. Infigratinib tablets to be administered by mouth.

  • Infigratinib 0.128 mg/kgDrug

    Subsequent cohort dose escalation based on protocol-specific criteria. Infigratinib tablets to be administered by mouth.

  • Infigratinib 0.25 mg/kgDrug

    Subsequent cohort dose escalation based on protocol-specific criteria. Infigratinib tablets to be administered by mouth.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs) that lead to dose decrease or discontinuationTime frame: Up to 18 months
  2. Change from baseline in annualized height velocityTime frame: Up to 18 months
  3. PK parameters of infigratinib (Cmax- PK substudy only)Time frame: 21 days
  4. PK parameters of infigratinib (Clast- PK substudy only)Time frame: 21 days
  5. PK parameters of infigratinib (Tmax- PK substudy only)Time frame: 21 days
  6. PK parameters of infigratinib (AUC24- PK substudy only)Time frame: 21 days
  7. PK parameters of infigratinib (T1/2- PK substudy only)Time frame: 21 days
  8. PK parameters of infigratinib (AUCinf- PK substudy only)Time frame: 21 days
  9. PK parameters of infigratinib (CL/F- PK substudy only)Time frame: 21 days
  10. PK parameters of infigratinib (Vz/F- PK substudy only)Time frame: 21 days
  11. PK parameters of infigratinib (Racc- PK substudy only)Time frame: 21 days

Locations

19 sites in 6 countries. Site status is shown where the registry gives one.

  • UCSF Benioff Children's Hospital

    Oakland, California

  • Nemours Alfred I. Dupont Hospital for Children

    Wilmington, Delaware

  • Johns Hopkins School of Medicine

    Baltimore, Maryland

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Murdoch Children's Hospital

    Parkville, Victoria, Australia

  • Stollery Children's Hospital

    Edmonton, Alberta, Canada

  • Hopital Femme Mere Enfant

    Lyon, France

  • Hopital Necker-Enfants Malades

    Paris, France

  • Hopital des Enfants

    Toulouse, France

  • Hospital Universitario La Paz

    Madrid, Spain

  • Hospital Universitario Virgen de la Victoria

    Málaga, Spain

  • Vithas Hospital San José

    Vitoria-Gasteiz, Álava, Spain

  • Birmingham Children's Hospital

    Birmingham, United Kingdom

  • University Hospitals Bristol and Weston NHS Foundation Trust

    Bristol, United Kingdom

  • Queen Elizabeth University Hospital

    Glasgow, United Kingdom

  • Evelina London Children's Hospital

    London, United Kingdom

  • Manchester University Children's Hospital

    Manchester, United Kingdom

  • Sheffield Children's Hospital

    Sheffield, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.